{
  "content": ". Despite these recommendations, the AIM-AF survey, which included responses from 629 physicians across the United States and Europe, found that 6% of physicians still choose Class Ic drugs as a typical treatment option for CAD patients . The 2020 ESC guidelines give a class I, level of evidence A recommendation for the use of amiodarone and dronedarone in patients with both AF and CAD . Notably, the most used tools for rhythm control in the above EAST-AFNET 4 trial and real-word registry cohort were amiodarone, flecainide, and ablation. These drugs, along with ablation procedures, were the most used methods for rhythm control in the EAST-AFNET 4 trial and subsequent real-world registry cohorts [5,6]",
  "source": "https://www.sciencedirect.com/science/article/pii/S0167527324008209",
  "chunk_id": "ae4582fd-8409-4a2b-814e-8d9a434203ca",
  "similarity_score": 0.38012170791625977,
  "query": "atrial fibrillation guidelines ESC AHA CCS amiodarone beta-blockers recommendations clinical practice first-line therapy",
  "rank": 14,
  "title": "The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease",
  "authors": "Shih-Rong Wang, Kuan-Chih Huang, Ting-Tse Lin, Shu-Lin Chuang, Yen-Yun Yang, Cho-Kai Wu, Lian-Yu Lin",
  "year": "2024",
  "journal": "International Journal of Cardiology",
  "reference": "Wang, S.-R., Huang, K.-C., Lin, T.-T., Chuang, S.-L., Yang, Y.-Y., Wu, C.-K., & Lin, L.-Y. (2024). The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease. International Journal of Cardiology, 409, 132198. https://doi.org/10.1016/j.ijcard.2023.132198",
  "doi": "10.1016/j.ijcard.2023.132198",
  "chunk_index": 13,
  "total_chunks": 92,
  "retrieved_at": "2025-07-24T21:58:06.270476"
}